2010 exhibitor list
|
Galderma | Stand: H12 |
|
Contact: Julian Popple Tel: 01923 208 950 Galderma (UK) Ltd Galderma is a global pharmaceutical company specialising in the research, development and marketing of corrective and aesthetic solutions for dermatology patients and is a leading player in the worldwide dermatology market. Created in 1981, Galderma is a joint venture between Nestlé and L’Oréal and employs more than 2,400 people. The company has wholly-owned affiliates in thirty-two countries and a worldwide network of exclusive sales agents. Committed to the future of dermatology Galderma’s ambition is to be recognised as the most competent and successful innovation-based company focused exclusively on meeting the needs of dermatology patients and physicians. “Just as the skin is a unique system within the human body, caring for the skin requires specialised knowledge and unique skills. At Galderma we are focused exclusively on advancing both the art and science of skincare. By providing physicians around the world with a full range of innovative products and services. By a commitment to researching leading-edge therapies to bring new innovations to market.” Product Portfolio Our growing portfolio includes treatment for major skin conditions – acne, rosacea, psoriasis, non-melanoma skin cancer and photodamage and hyperpigmentation disorders. Specific products include: • Azzalure®: A Botulinum toxin type A for the treatment of glabellar lines • Cetaphil®: a range of cleansing and moisturising products for all skin types. Originally formulated for dermatologists, they are gentle on your skin and sensitive to your skin’s needs • Calmurid® cream containing urea (10%) and lactic acid (5%) for the treatment of skin conditions characterized by dry, rough, scaly skin • Differin®: a topical retinoid containing adapalene (0.1%) available as a cream and a gel • Etrivex®: a short-contact corticosteroid shampoo for the treatment of scalp psoriasis • Loceryl®: a nail lacquer containing amorolfine (5%) for the treatment of fungal nail infections • Metvix®-PDT: a topical therapy for pre-cancerous and skin cancer lesions such as actinic keratoses, basal cell carcinomas and Bowen’s disease • Rozex®: metronidazole (0.75%) gel or cream for the treatment of rosacea • Silkis®: a topical treatment for mild to moderately severe plaque psoriasis • Tetralysal®: a once-daily oral antibiotic for the treatment of acne. • Efracea®: 40mg modified release doxycycline for treatment of papulospustular rosacea Corrective & Aesthetic Dermatology Galderma aims at becoming a worldwide leader in corrective and aesthetic dermatology by providing a full range of products and services to meet the increasing needs of the ageing population, who want to enhance their appearance and improve their quality of life. The evolution of science will lead to a better treatment of age-related diseases and facilitate a stronger emphasis on prevention and corrective treatments, allowing people to age more gracefully. Galderma want to be at the leading edge of this evolution. http://www.galderma.com Contact exhibitor |
||
